Viewing Study NCT05135312


Ignite Creation Date: 2025-12-26 @ 10:44 PM
Ignite Modification Date: 2025-12-26 @ 10:44 PM
Study NCT ID: NCT05135312
Status: UNKNOWN
Last Update Posted: 2022-01-06
First Post: 2021-11-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging
Sponsor: OptiSkin Medical
Organization:

Study Overview

Official Title: Monitoring Nail Changes in Patients With Psoriatic Disease Treated With Etanercept Using Non- Invasive Optical Coherence Tomography
Status: UNKNOWN
Status Verified Date: 2021-12
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with EnbrelĀ® (etanercept) with optical coherence tomography (OCT).
Detailed Description: Psoriasis often affects the fingernails, making them yellow, brittle, painful and prone to infections. These symptoms can be difficult to manage, so OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with EnbrelĀ® (etanercept) with optical coherence tomography (OCT).

OCT is being studied as a way to better diagnosis psoriatic nail disease, monitor response to therapy, and identify changes even before they become apparent, potentially leading to earlier treatment or prevention of future psoriatic arthritis.

Study-related care and medication are provided at no cost, and reimbursement for reasonable local transportation may be available to qualified individuals.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: